Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
- Revenue in GBP (TTM)--
- Net income in GBP--
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 19 3282 2000
- Websitehttps://www.haleon.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Teva Pharmaceutical Industries Ltd | 12.67bn | 1.03bn |
| Alnylam Pharmaceuticals, Inc. | 2.36bn | 32.00m |
| Sun Pharmaceutical Industries Ltd | 4.61bn | 850.80m |
| Haleon PLC | -100.00bn | -100.00bn |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.28bn | 790.58m |
| Bayer AG | 39.81bn | -171.87m |
| Takeda Pharmaceutical Co Ltd | 20.86bn | 527.63m |
| Zoetis Inc | 6.90bn | 1.95bn |
| UCB SA | 5.94bn | 1.16bn |
| CSL Ltd | 11.58bn | 2.23bn |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 23 Sep 2025 | 359.60m | 4.04% |
| Dodge & Coxas of 30 Sep 2024 | 233.28m | 2.62% |
| The Vanguard Group, Inc.as of 01 Jan 2026 | 223.09m | 2.51% |
| BlackRock Fund Advisorsas of 06 Mar 2025 | 196.79m | 2.21% |
| BlackRock Investment Management (UK) Ltd.as of 01 Jan 2026 | 181.50m | 2.04% |
| MFS International (UK) Ltd.as of 01 Jan 2026 | 172.01m | 1.93% |
| Harding Loevner LPas of 01 Jan 2026 | 132.71m | 1.49% |
| Franklin Mutual Advisers LLCas of 01 Jan 2026 | 131.98m | 1.48% |
| Norges Bank Investment Managementas of 01 Jan 2026 | 129.69m | 1.46% |
| First Eagle Investment Management LLCas of 01 Jan 2026 | 127.54m | 1.43% |
